Basilea Pharmaceutica (OTCMKTS:BPMUF) Upgraded at HC Wainwright

HC Wainwright upgraded shares of Basilea Pharmaceutica (OTCMKTS:BPMUF) to a strong-buy rating in a research report sent to investors on Monday, Zacks.com reports.

Basilea Pharmaceutica Price Performance

BPMUF stock opened at $51.26 on Monday. The business’s 50-day moving average is $49.47 and its two-hundred day moving average is $46.70. Basilea Pharmaceutica has a 1 year low of $38.60 and a 1 year high of $51.26.

About Basilea Pharmaceutica

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.